Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) can alter menstrual cycles in some women, most commonly causing irregular timing, heavier or lighter bleeding, or missed periods, particularly in the first few months of treatment. These changes are not listed as a direct drug side effect in the SmPC, but they are real, reported widely, and have an explainable biological basis. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The mechanism is almost certainly indirect. Tirzepatide acts on GIP and GLP-1 receptors to reduce appetite and slow gastric emptying, which leads, in many people, to meaningful weight loss over a relatively short period. Fat tissue is hormonally active: it produces and converts oestrogen. When it shrinks quickly, oestrogen levels shift, and the hypothalamic signals that govern the monthly cycle respond to that shift. The result is often a temporarily disrupted pattern, in the same way that intensive training, a significant illness, or rapid dietary change can delay or alter a period.
The drug itself has no known direct action on ovarian or uterine tissue, so framing Mounjaro as "a medicine that messes with your hormones" misses the point. It is the body adapting to change. For most women, cycles settle once weight and the associated hormone environment reach a new steady state. If you want to understand more about how tirzepatide works in the body, the tirzepatide overview covers the mechanism in full.
The NHS patient information page for tirzepatide does not list menstrual irregularity as a recognised adverse effect, which reflects the clinical trial populations rather than a signal that the changes are rare in real-world use.
Broadly, there are three common patterns. The first is a delayed or skipped period, especially in the first two or three months. The second is a heavier or more painful period than usual, which can happen when the cycle resumes after a gap. The third, and perhaps the most significant, is cycle regularisation in women who previously had infrequent or absent periods because of PCOS.
PCOS is closely tied to insulin resistance and excess adipose tissue. Tirzepatide addresses both. As weight falls and insulin sensitivity improves, the hormonal environment can shift enough to restart regular ovulation. Clinically, that is good news; practically, it means a woman who had not ovulated regularly for years may begin doing so again. Missing a period on Mounjaro is a separate question worth reading if that is your specific situation.
A common misconception worth gently setting aside: heavier bleeding during early treatment does not mean the treatment is harming you. In most cases it is the uterine lining catching up after a delayed cycle, not a sign that something has gone wrong with the medicine. If you are curious about the broader picture of how Mounjaro can change your period, including what counts as typical variation and what sits outside it, that page brings together the detail in one place.
This is the part that genuinely matters for safety planning. The MHRA and NHS England guidance is clear: women taking oral contraceptives should use an additional non-oral method, such as condoms, for the first four weeks of tirzepatide treatment and for four weeks after every dose increase. Tirzepatide slows gastric emptying, which can reduce how reliably the pill is absorbed in those windows. The NHS England guidance on weight-management injections covers this point directly.
The same concern does not apply equally to semaglutide, where equivalent evidence of reduced pill absorption has not emerged. If you are on tirzepatide and rely on the pill as your sole contraception, the missed-window risk is real. Patches, implants, or coil are unaffected by gastric motility, so switching forms removes the issue entirely. Discuss the options with your GP or our prescriber team before your next dose increase.
There is also the fertility angle. If your cycles were irregular before treatment and tirzepatide restores regular ovulation, unintended pregnancy becomes a live possibility. A positive pregnancy test during treatment means stopping immediately and speaking to your GP, because Mounjaro is not recommended in pregnancy.
Most cycle changes on tirzepatide resolve without intervention. You do not need to contact anyone because your period was a week late after starting. However, some situations do warrant prompt attention. Seek medical advice if you have very heavy bleeding that soaks through more than one pad or tampon per hour for two or more hours, if bleeding is accompanied by severe pain that is new or different from your normal experience, if you have no period for three or more consecutive months and you are not already post-menopausal, or if you have any symptoms that feel unexplained alongside the menstrual change, such as the sudden visual disturbances covered on the Mounjaro and vision changes page.
You can report any suspected side effect directly through the MHRA's Yellow Card scheme. Mounjaro carries a Black Triangle (▼) designation, meaning extra monitoring applies and reports from patients are actively welcomed.
If you are already on Mounjaro and want a prescriber to review your situation, or if progress has slowed and you are wondering whether your weight being stuck on Mounjaro is connected to hormonal changes, you are welcome to speak to our prescribers directly. Every consultation at nume is reviewed by a real clinician the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.